Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2004 2
2005 1
2006 1
2007 2
2008 5
2009 8
2010 7
2011 6
2012 7
2013 6
2014 5
2015 2
2016 6
2017 2
2018 2
2019 5
2020 4
2021 3
2022 4
2023 3
2024 4
2025 6
2026 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

82 results

Results by year

Filters applied: . Clear all
The following term was not found in PubMed: oledronic
Page 1
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS-2020 UPDATE.
Camacho PM, Petak SM, Binkley N, Diab DL, Eldeiry LS, Farooki A, Harris ST, Hurley DL, Kelly J, Lewiecki EM, Pessah-Pollack R, McClung M, Wimalawansa SJ, Watts NB. Camacho PM, et al. Endocr Pract. 2020 May;26(Suppl 1):1-46. doi: 10.4158/GL-2020-0524SUPPL. Endocr Pract. 2020. PMID: 32427503
New or updated topics in this CPG include: clarification of the diagnosis of osteoporosis, stratification of the patient according to high-risk and very-high-risk features, a new dual-action therapy option, and transitions from therapeutic options. ...Food and Drug Adminis …
New or updated topics in this CPG include: clarification of the diagnosis of osteoporosis, stratification of the patient according to …
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.
Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR; HORIZON Pivotal Fracture Trial. Black DM, et al. N Engl J Med. 2007 May 3;356(18):1809-22. doi: 10.1056/NEJMoa067312. N Engl J Med. 2007. PMID: 17476007 Free article. Clinical Trial.
BACKGROUND: A single infusion of intravenous zoledronic acid decreases bone turnover and improves bone density at 12 months in postmenopausal women with osteoporosis. ...RESULTS: Treatment with zoledronic acid reduced the risk of morphometric vertebral …
BACKGROUND: A single infusion of intravenous zoledronic acid decreases bone turnover and improves bone density at 12 months in pos …
The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT).
Black DM, Reid IR, Boonen S, Bucci-Rechtweg C, Cauley JA, Cosman F, Cummings SR, Hue TF, Lippuner K, Lakatos P, Leung PC, Man Z, Martinez RL, Tan M, Ruzycky ME, Su G, Eastell R. Black DM, et al. J Bone Miner Res. 2012 Feb;27(2):243-54. doi: 10.1002/jbmr.1494. J Bone Miner Res. 2012. PMID: 22161728 Free PMC article. Clinical Trial.
Zoledronic acid 5 mg (ZOL) annually for 3 years reduces fracture risk in postmenopausal women with osteoporosis. To investigate long-term effects of ZOL on bone mineral density (BMD) and fracture risk, the Health Outcomes and Reduced Incidence with Zoledronic …
Zoledronic acid 5 mg (ZOL) annually for 3 years reduces fracture risk in postmenopausal women with osteoporosis. To inv …
ERN ReCONNET-SLICC-SLEuro expert consensus on the therapeutic management of rare systemic lupus erythematosus manifestations.
Arnaud L, Ruiz-Irastorza G, Aranow C, Bernatsky S, Dall'Era M, Adelowo O, Bae SC, Beretta L, Bonfa E, Cervera R, Chasset F, Clarke AE, Costedoat-Chalumeau N, Doria A, Espinosa G, Fanouriakis A, Fredi M, Gatto M, Gladman DD, Gomez-Puerta JA, Inanç M, Ines LS, Isenberg D, Izuka S, Khmelinskii N, Legge A, Macieira C, Monticielo OA, Morand EF, Muñoz-Louis R, Padjen I, Petri M, Piga M, Pons-Estel BA, Ramirez GA, Ramsey-Goldman R, Richez C, Sciascia S, Toro-Gutierrez CE, Van Vollenhoven RF, Vital EM, Gerosa M, Touma Z, Mosca M, Tani C; European Reference Network on Rare and Complex Connective Tissue and Musculoskeletal, Diseases; Systemic Lupus Erythematosus International Collaborating Clinics group; European Lupus Society rare systemic lupus erythematosus taskforce member panel. Arnaud L, et al. Lancet Rheumatol. 2025 Jul;7(7):e505-e518. doi: 10.1016/S2665-9913(25)00063-3. Epub 2025 May 23. Lancet Rheumatol. 2025. PMID: 40418946 Review.
Pathophysiology of Demineralization, Part I: Attrition, Erosion, Abfraction, and Noncarious Cervical Lesions.
Roberts WE, Mangum JE, Schneider PM. Roberts WE, et al. Curr Osteoporos Rep. 2022 Feb;20(1):90-105. doi: 10.1007/s11914-022-00722-1. Epub 2022 Feb 7. Curr Osteoporos Rep. 2022. PMID: 35129809 Free PMC article. Review.
Demineralization is the most prevalent chronic disease in the world: osteoporosis (OP) >10%, dental caries ~100%. OP is severely debilitating while caries is potentially fatal. ...Controlling demineralization at all levels is an important horizon for cost-effecti …
Demineralization is the most prevalent chronic disease in the world: osteoporosis (OP) >10%, dental caries ~100%. OP is severely d …
Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research.
Adler RA, El-Hajj Fuleihan G, Bauer DC, Camacho PM, Clarke BL, Clines GA, Compston JE, Drake MT, Edwards BJ, Favus MJ, Greenspan SL, McKinney R Jr, Pignolo RJ, Sellmeyer DE. Adler RA, et al. J Bone Miner Res. 2016 Jan;31(1):16-35. doi: 10.1002/jbmr.2708. J Bone Miner Res. 2016. PMID: 26350171 Free PMC article. Review.
In the HORIZON extension, women who received 6 annual infusions of zoledronic acid had fewer morphometric vertebral fractures compared with those switched to placebo after 3 years. ...The suggested approach for long-term BP use is based on limited evidence, only for …
In the HORIZON extension, women who received 6 annual infusions of zoledronic acid had fewer morphometric vertebral fractures …
Bisphosphonates and lifespan.
Center JR, Lyles KW, Bliuc D. Center JR, et al. Bone. 2020 Dec;141:115566. doi: 10.1016/j.bone.2020.115566. Epub 2020 Jul 31. Bone. 2020. PMID: 32745686 Review.
Bisphosphonates are first line agents used to treat osteoporosis and reduce fracture rate. They bind to areas of exposed calcium in the skeleton and cause osteoclast apoptosis, thereby leading to a reduction in remodelling rates. ...This review will consider the clinical e …
Bisphosphonates are first line agents used to treat osteoporosis and reduce fracture rate. They bind to areas of exposed calcium in t …
The role of zoledronic acid in the management of osteoporosis.
Maricic M. Maricic M. Clin Rheumatol. 2010 Oct;29(10):1079-84. doi: 10.1007/s10067-010-1486-3. Epub 2010 Jun 11. Clin Rheumatol. 2010. PMID: 20544246 Review.
Zoledronic acid (ZOL) 5 mg, a once-yearly intravenous bisphosphonate, is approved for treatment and prevention of postmenopausal osteoporosis, increasing bone mass in men with osteoporosis, and treatment and prevention of glucocorticoid-induced oste …
Zoledronic acid (ZOL) 5 mg, a once-yearly intravenous bisphosphonate, is approved for treatment and prevention of postmenopausal …
The Interaction of Acute-Phase Reaction and Efficacy for Osteoporosis After Zoledronic Acid: HORIZON Pivotal Fracture Trial.
Black DM, Reid IR, Napoli N, Ewing SK, Shiraki M, Nakamura T, Takeuchi Y, Schafer AL, Kim TY, Cauley JA. Black DM, et al. J Bone Miner Res. 2022 Jan;37(1):21-28. doi: 10.1002/jbmr.4434. Epub 2021 Sep 28. J Bone Miner Res. 2022. PMID: 34585443 Free PMC article. Clinical Trial.
Zoledronic acid (ZOL) as a yearly infusion is effective in reducing fracture risk. An acute-phase reaction (APR), consisting of flu-like symptoms within 3 days after infusion, is commonly seen. ...This analysis uses data from the 3-year randomized clinical trial, Health Ou …
Zoledronic acid (ZOL) as a yearly infusion is effective in reducing fracture risk. An acute-phase reaction (APR), consisting of flu-l …
New anabolic therapies for osteoporosis.
Minisola S, Cipriani C, Occhiuto M, Pepe J. Minisola S, et al. Intern Emerg Med. 2017 Oct;12(7):915-921. doi: 10.1007/s11739-017-1719-4. Epub 2017 Aug 5. Intern Emerg Med. 2017. PMID: 28780668 Review.
Osteoporosis is characterized by low bone mass and qualitative structural abnormalities of bone tissue, leading to increased bone fragility that results in fractures. ...The only currently available drug licensed is parathyroid hormone 1-34 (teriparatide); new drugs are on …
Osteoporosis is characterized by low bone mass and qualitative structural abnormalities of bone tissue, leading to increased bone fra …
82 results